Last week the European Medicines Agency (EMEA) backed the GSK vaccine Pandemrix, of which the DoH has ordered 60 million doses, for use in at-risk groups.
The second vaccine to be used in the UK, produced by Baxter, is expected to receive EMEA approval in the next few days.
However, the European Commission has still to grant EU-wide marketing authorisation for the vaccines.
A spokeswoman for the DoH confirmed that the vaccination programme cannot begin until the commission backs the jabs.
‘The European Commission must now consider the recommendations and we hope for their decision as quickly as possible,' she said.
Dr Peter Holden, GPC lead for pandemic flu, told GP: ‘We are no further forward with the vaccination campaign.
‘My understanding is that it will take a further six weeks for the vaccine to go through the European Commission. We are not yet ready to run the vaccination campaign.'
But Dr Holden added that the longer it takes for the vaccine to be available on the NHS, the more secure supplies will be.
‘There will be a buffer of stock. What we do not want to see is a vaccination campaign that stalls when the vaccine supplies run out.'
Speaking to GP before the EMEA announcement, CMO for England Sir Liam Donaldson said he was sure the vaccination programme would start in October.
Health Protection Agency data show 9,200 confirmed cases of swine flu last week, almost a doubling of cases from the week before.
It is believed that the rise is being fuelled by children returning to school, with 66 school outbreaks reported since the start of the autumn term.
A huge surge in the number of cases across France has been reported in the last two weeks.
Read the full version of this story in this week's edition of GP dated 2 October